The cystic fibrosis (CF) market is poised for significant change. The next generation of CF treatments all
target the central mechanism responsible for organ damage in CF. These agents, as one thought leader states,
“represent the closest we have come to a cure for CF” and will almost certainly bring about a change in the
treatment algorithm of the disease. As a result, new market leaders will emerge, and current first-line therapies
will find themselves relegated to second- or third-line options.
Get the Answers You Need to Shape Your Strategy
Physicians use a variety of medications and nonpharmacological treatments to address the needs of CF
patients. What are the strengths and weaknesses of these treatments? Which work best in specific
subpopulations? Do thought leaders believe these treatments will still have a role in the treatment
algorithm over the next five to ten years?
Several drugs with trusted and novel mechanisms of action are in development for CF. What new agents are
in development? What are thought leaders’ opinions of the potential of these agents in the treatment of
CF? What impact will these agents have on treatment algorithms and the CF market?
Emerging agents target the central mechanism responsible for organ damage in CF and have the potential
to be disease modifying rather than just treating symptoms. What unmet needs remain in drug
development? Will the formulations of these emerging therapies improve patient compliance? What
more is required to effectively treat the pediatric subpopulation?
Scope
Overview of CF: disease development, symptoms, complications, and methods for diagnosis.
Epidemiology: disease definition; incidence by race; growth in the number of prevalent cases.
Current therapies: mucolytics, antibiotics, pancreatic enzyme replacement therapy, as well as
thought leaders’ opinions on where these agents fit into the treatment algorithm.
Emerging therapies: strengths and weaknesses of agents in development; novel mechanisms of
action; an analysis of market position for these agents.
CF market: details on the 2007 market and prescribing trends.
Outlook: the impact of novel agents on the CF market.
Orphan Disease Series: As competition increases in larger disease states, companies are turning
to orphan diseases that offer substantial pricing advantages and lower regulatory hurdles because
of high unmet need. The Orphan Disease Series provides critical market information, including
disease prevalence, profiles of marketed and emerging agents, and insight into the prescribing
choices of disease specialists for diseases with smaller patient populations. These reports will help
you to maximize the potential of your agents in these challenging markets, including the regulatory
benefits available and the potential for partnership with charitable organizations.
(0 items)
